Last reviewed · How we verify
Primary nocturnal enuresis
At a glance
| Generic name | Primary nocturnal enuresis |
|---|---|
| Sponsor | Ferring Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Serum Copeptin as Biomarker for Diagnosis and Classification of Polyuric Primary Monosymptomatic Nocturnal Enuresis
- Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency (NA)
- Hidden Link Between Meatal Stenosis and Primary Nocturnal Enuresis in Children
- Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE (PHASE3)
- The Behavioral Therapy for Primary Monosymptomatic Nocturnal Enuresis
- A Cohort Study on Treating Primary Nocturnal Enuresis by Regulating Central-Peripheral Circadian Rhythm (NA)
- Comparative Study of the Efficacy of TENS Versus Placebo in Isolated Primary Enuresis (NA)
- Effectiveness of Pelvic Floor Muscle Rehabilitation Combined With Desmopressin in Children With Primary Monosymptomatic Nocturnal Enuresis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Primary nocturnal enuresis CI brief — competitive landscape report
- Primary nocturnal enuresis updates RSS · CI watch RSS
- Ferring Pharmaceuticals portfolio CI